Can a meta-analysis that mixes apples with oranges be used to demonstrate that levosimendan reduces mortality after coronary revascularization?

Critical Care

Volumn 15, Issue 6, 2011, Pages

  Meco, Massimo ^a   Cirri, Silvia ^b  

^a ISTITUTO CLINICO SANT'AMBROGIO   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOSIMENDAN; PLACEBO; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE;

CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; DRUG EFFICACY; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC PRECONDITIONING; LETTER; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORTALITY; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; CARDIOVASCULAR DISEASE; NOTE;

CARDIOVASCULAR DISEASES; HUMANS; HYDRAZONES; MYOCARDIAL REVASCULARIZATION; PYRIDAZINES;

EID: 83755171704     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10484     Document Type: Letter

References (9)

1. Maharaj R, Metaxa V. Levosimendan and mortality after coronary revascularization: a meta-analysis of randomised controlled trials. Crit Care 2011, 15:R140. 10.1186/cc10263, 3219012, 21651806.
2. Green S. Systematic reviews and meta-analysis. Singapore Med J 2005, 46:270-273.
3. Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D. Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol 2004, 44:703-708. 10.1097/00005344-200412000-00013, 15550791.
4. De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007, 104:766-773. 10.1213/01.ane.0000256863.92050.d3, 17377079.
5. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, Singer M. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 2009, 102:198-204. 10.1093/bja/aen367, 19151048.
6. Aiello F, Attanasio M, Tine F. Assessing covariate imbalance in meta-analysis studies. Stat Med 2011, 30:2671-2682. 10.1002/sim.4311, 21786283.
7. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994, 309:1351-1355. 10.1136/bmj.309.6965.1351, 2541868, 7866085.
8. Macarthur C, Foran PJ, Bailar JC. Qualitative assessment of studies included in a meta-analysis: DES and the risk of pregnancy loss. J Clin Epidemiol 1995, 48:739-747. 10.1016/0895-4356(94)00190-2, 7769404.
9. Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2011, [Epub ahead of print].